Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | SHBG | P04278 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7196165 | 1.00 | AR (0.44) | ARKCNH2GRIN1GRIN2BNR3C1 | |
| SCHEMBL3486294 | 0.87 | GRIN1 (0.47) | ARGRIN1GRIN2BNR3C1SHBG | |
| SCHEMBL7197702 | 0.83 | AR (0.42) | ARGPBAR1 | |
| SCHEMBL7515861 | 0.83 | MEN1 (0.40) | ARKCNH2NR3C1PGRCYP3A4 | |
| SCHEMBL7515870 | 0.83 | MEN1 (0.40) | ARKCNH2NR3C1PGRCYP3A4 | |
| SCHEMBL11329429 | 0.83 | AR (0.42) | ARNR3C1SHBGPGRSERPINA6 | |
| SCHEMBL11329447 | 0.83 | AR (0.42) | ARNR3C1SHBGPGRSERPINA6 | |
| SCHEMBL7195422 | 0.82 | GPBAR1 (0.43) | ARGPBAR1HSD17B10 | |
| SCHEMBL21807712 | 0.81 | AR (0.45) | ARKCNH2GRIN1GRIN2BNR3C1 | |
| SCHEMBL8898529 | 0.81 | AR (0.45) | ARKCNH2GRIN1GRIN2BNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134828-A1 | Composition and method for increasing in vivo androgen concentration | ROBERTS WILLIAM J (US) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134828-A1 | Composition and method for increasing in vivo androgen concentration | SHBG, CYP21A2, CYP19A1 | AR 6/4885KCNH2 4598/4885GRIN1 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.